“The adverse effects of SERMs pale in comparison to the complications of and disability caused by breast cancer,” Dr. Hortobagyi said. “So the challenge today is how to communicate to the public to enhance the utilization of SERMs and reduce further the incidence of breast cancer.”
Disclosures: The study was supported by the National Cancer Institute. Dr. Wickerham reported that he has consulted for Eli Lilly. Dr. Hortobagyi reported no conflicts of interest.
“These data are good news,” Dr. D. Lawrence Wickerham commented.
Source: Kerri Wachter/Elsevier Global Medical News